Novo Nordisk shares jump about 4% after EMA panel backs Frehemgo
Novo Nordisk (NVO) shares rose about 4% after a European Medicines Agency panel recommendation for Frehemgo (denecimig), its next-generation haemophilia A treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.